Furthermore, the subtype concept based on biological testing has promoted combination therapy with anti-cancerous drug and molecular target agents like TZ, which is inevitably important for HER2-positive breast cancer and results in high pCR rates [8]. Here, ERBB2 is linked to breast carcinoma.